Research

Importantly, the investigators went on to identify two FDA-approved medications that could obstruct the dangerous process. They say these drugs could suggest new directions in TBI and Alzheimer’s research and treatment.

Now, scientists at the Department of Defense, VA, and partner institutions are testing a new technology to treat COVID-19. It’s called the Seraph 100 blood filter. The treatment uses a novel approach to filter out viral particles and harmful molecules from the bloodstream of COVID-19 patients.

COPD is a group of respiratory diseases that limit airflow and make it hard to breathe. It’s usually linked to an abnormal inflammatory response in the lungs to noxious particles or gases, such as cigarette smoke.

In a secondary analysis, Kremen and his colleagues looked at brain images while controlling for the effects of general aging. They observed that the Alzheimer’s-related brain regions remained as significant predictors, suggesting that the effect was not simply due to general aging.

Well-designed and rigorous clinical trials are the gold standard for providing evidence of a medical treatment’s safety and effectiveness. They are the basis for FDA approval of new drugs and medical devices.

The study’s principal investigator, Dr. Dan Blalock, says one possible explanation for the finding is that healthier patients in the study sample liked to drink in moderate amounts.

The Tuscaloosa VA Research and Development Department's supported employment program, matched with primary care, studied how best to match Veterans with gainful employment.

The team looked at the records of Veterans already identified as high-risk by VA’s sophisticated Care Assessment Needs (CAN) calculator. The CAN tool provides a score reflecting a Veteran’s risk of hospitalization or death within a year.

Singh is a professor at Baylor College of Medicine and an investigator at the Center for Innovations in Quality, Effectiveness and Safety (IQuESt), a VA-funded research center at the DeBakey VA Medical Center.

A growing body of research is showing that brief psychological treatments designed to combat myths regarding the danger of physical symptoms of anxiety, coupled with repeated exposure to these sensations, can lead to reductions in anxiety sensitivity, according to Ennis.

The executive order notes, "Each federal agency must assess whether, and to what extent, its programs and policies perpetuate systemic barriers to opportunities and benefits for people of color and other underserved groups."

I’m involved in prostate cancer basic research and new drug development. Prostate cancer is the most common non-skin cancer in Veterans. About 35,000 Veterans with prostate cancer receive treatment in the VA system.